14:33:24 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-12-05 Årsstämma 2025
2024-11-05 Bokslutskommuniké 2024
2024-08-20 Kvartalsrapport 2024-Q3
2024-05-13 X-dag halvårsutdelning COLO B 5
2024-05-07 Kvartalsrapport 2024-Q2
2024-02-09 Kvartalsrapport 2024-Q1
2023-12-08 X-dag halvårsutdelning COLO B 16
2023-12-07 Årsstämma 2024
2023-11-09 Bokslutskommuniké 2023
2023-08-17 Kvartalsrapport 2023-Q3
2023-05-15 X-dag halvårsutdelning COLO B 5
2023-05-11 Kvartalsrapport 2023-Q2
2023-02-03 Kvartalsrapport 2023-Q1
2022-12-02 X-dag halvårsutdelning COLO B 15
2022-12-01 Årsstämma 2023
2022-11-07 Bokslutskommuniké 2022
2022-08-17 Kvartalsrapport 2022-Q3
2022-05-09 X-dag halvårsutdelning COLO B 5
2022-05-05 Kvartalsrapport 2022-Q2
2022-01-25 Kvartalsrapport 2022-Q1
2021-12-03 X-dag halvårsutdelning COLO B 14
2021-12-02 Årsstämma 2022
2021-11-01 Bokslutskommuniké 2021
2021-08-18 Kvartalsrapport 2021-Q3
2021-05-10 X-dag halvårsutdelning COLO B 5
2021-05-06 Kvartalsrapport 2021-Q2
2021-02-06 Kvartalsrapport 2021-Q1
2020-12-04 X-dag halvårsutdelning COLO B 13
2020-12-03 Årsstämma 2021
2020-11-03 Bokslutskommuniké 2020
2020-08-18 Kvartalsrapport 2020-Q3
2020-05-11 X-dag halvårsutdelning COLO B 5
2020-05-06 Kvartalsrapport 2020-Q2
2020-02-06 Kvartalsrapport 2020-Q1
2019-12-06 X-dag halvårsutdelning COLO B 12
2019-12-05 Årsstämma 2020
2019-11-05 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q3
2019-05-06 X-dag halvårsutdelning COLO B 5
2019-05-02 Kvartalsrapport 2019-Q2
2019-02-05 Kvartalsrapport 2019-Q1
2018-12-06 X-dag halvårsutdelning COLO B 11
2018-12-05 Årsstämma 2019
2018-11-01 Bokslutskommuniké 2018
2018-08-08 Kvartalsrapport 2018-Q3
2018-05-07 X-dag halvårsutdelning COLO B 5
2018-05-03 Kvartalsrapport 2018-Q2
2018-02-01 Kvartalsrapport 2018-Q1
2017-12-08 X-dag halvårsutdelning COLO B 10.5
2017-12-07 Årsstämma 2018
2017-11-02 Bokslutskommuniké 2017
2017-08-16 Kvartalsrapport 2017-Q3
2017-05-08 X-dag halvårsutdelning COLO B 4.5
2017-05-03 Kvartalsrapport 2017-Q2
2017-02-01 Kvartalsrapport 2017-Q1
2016-12-06 X-dag halvårsutdelning COLO B 9
2016-12-05 Årsstämma 2017
2016-11-02 Bokslutskommuniké 2016
2016-08-16 Kvartalsrapport 2016-Q3
2016-05-09 X-dag halvårsutdelning COLO B 4.5
2016-05-03 Kvartalsrapport 2016-Q2
2016-02-02 Kvartalsrapport 2016-Q1
2015-12-10 X-dag halvårsutdelning COLO B 8
2015-12-09 Årsstämma 2016
2015-11-03 Bokslutskommuniké 2015
2015-08-11 Kvartalsrapport 2015-Q3
2015-05-07 X-dag halvårsutdelning COLO B 4.5
2015-05-05 Kvartalsrapport 2015-Q2
2015-01-29 Kvartalsrapport 2015-Q1
2014-12-05 X-dag halvårsutdelning COLO B 7.5
2014-12-04 Årsstämma 2015
2014-10-30 Bokslutskommuniké 2014
2014-05-08 X-dag halvårsutdelning COLO B 4
2013-12-06 X-dag halvårsutdelning COLO B 7
2013-12-05 Årsstämma 2014
2013-10-31 Bokslutskommuniké 2013
2013-08-13 Kvartalsrapport 2013-Q3
2013-05-06 X-dag halvårsutdelning COLO B 3
2013-04-30 Kvartalsrapport 2013-Q2
2013-01-30 Kvartalsrapport 2013-Q1
2012-12-19 Split COLO B 1:5
2012-12-11 Årsstämma 2013
2012-11-06 Bokslutskommuniké 2012
2012-08-15 Kvartalsrapport 2012-Q3
2012-04-26 Kvartalsrapport 2012-Q2
2012-01-25 Kvartalsrapport 2012-Q1
2011-12-08 X-dag ordinarie utdelning COLO B 14.00 DKK
2011-12-07 Årsstämma 2012
2011-11-01 Bokslutskommuniké 2011
2011-08-17 Kvartalsrapport 2011-Q3
2011-06-21 Kapitalmarknadsdag 2011
2011-05-04 Kvartalsrapport 2011-Q2
2011-01-26 Kvartalsrapport 2011-Q1
2010-12-02 X-dag ordinarie utdelning COLO B 10.00 DKK
2009-12-02 X-dag ordinarie utdelning COLO B 7.00 DKK
2004-12-16 Split COLO B 1:2

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Coloplast är verksamt inom medicinteknik. Bolaget är en utvecklare av produkter och tjänster anpassade för människor med olika medicinska tillstånd. Bolagets produktportfölj består av vårdutrustning och används huvudsakligen inom områdena stomi, inkontinens, urologi, samt hud- och sårvård. Idag är bolaget verksamma på en global marknad via egna försäljningskanaler. Bolaget grundades 1954 och har sitt huvudkontor i Humlebæk, Danmark.
2024-05-14 09:30:00

The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2.

Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women.

“So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients3, and seven out of ten users feel confident that it empties their bladder completely without needing to reposition the catheter4,” says Nicolai Buhl, Executive Vice President of Innovation.

Urinary tract infections remain a major concern and challenge for men and women using catheters5. Flow stops and blockage of conventional catheter eyelets during catheterisation increase the risk of leaving residual urine behind in the bladder, which raises the risk of bacteria growth and is a well-known UTI risk factor2.

“I am excited that the Micro-hole Zone Technology will now be available for female catheter users. The new female catheter has 50+ micro-holes*, enabling complete bladder emptying in one free flow1, and I believe this technology will set a completely new standard in the market,” says Nicolai Buhl.

Luja with Micro-hole Zone Technology for female users will launch across all Coloplast’s key markets over the next 12 months, starting in Denmark and Italy in May 2024**.

Clinical studies: No need for repositioning and no discomfort
The performance of Luja for women is supported by two clinical studies. The studies found that the catheter enables complete bladder emptying in one free flow without having to reposition the catheter1. The studies also found that women reported no discomfort when using Luja and that the catheter was gentle to use6.

Reduced environmental footprint
Luja Female is designed with the user and environment in mind. The catheter is made with 28% less plastic than Coloplast’s SpeediCath® Compact Eve and has a 22% lower carbon footprint7. The Luja Female product container material is recyclable8.

Contacts
Peter Mønster
Sr. Media Relations Manager
+45 4911 2623
dkpete@coloplast.com

Aleksandra Dimovska
Sr. Director of Investor Relations
+45 4911 2458
dkadim@coloplast.com

References
1Luja female ensured zero flow stops in 87% of catheterisations & <10 mL residual urine at first flow stop in 83% of catheterisations (RCTs, post-hoc, NCT05841004, n=73, & NCT05814211, n=82). Coloplast Data-on-File, 01/2024. Individual
results may vary.

2UTI risk factors defined by Kennelly M, Thiruchelvam N, Averbeck MA et al. Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections, Adv Urol., 2019; 2:2019:2757862

3Vaabengaard R, Islamoska S, Zeeberg R, Jacobsen L. Healthcare professionals feel confident and less worried about bladder emptying and urinary tract infections when patients use the micro-hole zone catheter Luja™. BAUN Annual Conference, AAC, Liverpool, UK 2023. PM-28201, n = 62.​

4Vaabengaard R, Islamoska S, Zeeberg R, Jacobsen L. Users of intermittent catheters feel more confidence and less worries of bladder emptying and urinary tract infections when using the micro-hole zone catheter Luja™. BAUN Annual Conference, AAC, Liverpool, UK 2023. PM-28203, n = 816.

5Averbeck MA, Kennelly M, Thiruchelvam N et al. Risk factors for urinary tract infections associated with lower quality of life among intermittent catheter users. British Journal of Nursing, 2023, Vol 32, No 18 (Urology Supplement).

6Coloplast Data-on-File, RCT, NCT05814211, 03/2024, n=82

7Compared to SpeediCath® Compact Eve. Based on externally reviewed carbon footprint according to ISO14067.

8Product design, use and local waste management specifics may limit recyclability.

*minimum of 50 micro-holes on Luja female CH10-16.

**Luja for female users is a medical device for which the CE-mark has been affixed. Product availability is subject to the regulatory process of individual countries and is not guaranteed. The product is currently not available in the US.